Profile: Abbott Laboratories (ABT)
19 Dec 2014
Abbott Laboratories (Abbott), incorporated on March 6, 1900, is engaged in the discovery, development, manufacture, and sale of a range of healthcare products. Abbott operates in four business segments: established pharmaceutical products, diagnostic products, nutritional products, and vascular products.
Established Pharmaceutical Products
Established pharmaceutical products include a range of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States, and are sold directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses, depending on the market served. Certain products are co-marketed or co-promoted with other companies. The segment’s broad therapeutic area portfolio of products include gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines.
The Company’s gastroenterology products include Creon, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis; Duspatal and Dicetel, for the treatment of irritable bowel syndrome or biliary spasm; Adomet, Heptral, Transmetil, Samyr and Donamet, for the treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms; and Duphalac, for regulation of the physiological rhythm of the colon. Its women's health products include Duphaston, for the treatment of many different gynecological disorders; and Femoston, a hormone replacement therapy for postmenopausal women. Cardiovascular and metabolic products include Lipanthyl and TriCor, for the treatment of dyslipidemia; Teveten and Teveten Plus, for the treatment of essential hypertension, and Physiotens, for the treatment of hypertension; and Synthroid, for the treatment of hypothyroidism. Pain and central nervous system products include Serc, for the treatment of Meniere's disease and vestibular vertigo; and Brufen, for the treatment of pain, fever, and inflammation. The Company’s respiratory drugs and vaccines include the anti-infective clarithromycin (sold under the trademarks Biaxin, Klacid, and Klaricid); and Influvac, an influenza vaccine available during flu season.
Diagnostic products include a range of diagnostic systems and tests manufactured, marketed, and sold worldwide to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate-care testing sites, and plasma protein therapeutic companies. In the United States, the segment's products are marketed and sold directly from Abbott-owned distribution centers, public warehouses and third-party distributors. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.
Diagnostic products segment’s products include immunoassay and clinical chemistry systems, including ARCHITECT and ABBOTT PRISM; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases such as hepatitis and HIV; a full line of hematology systems and reagents known as the Cell-Dyn series; the m2000, an instrument that automates the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents including HIV, HBV, HCV, HPV, and CT/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit, the UroVysion bladder cancer recurrence kit, and the Vysis ALK Break Apart FISH Probe Kit, the only FDA-approved companion diagnostic to Pfizer's approved non-small-cell lung cancer therapy XALKORI; informatics and automation solutions for use in the laboratory; and the i-STAT point-of-care diagnostic systems and tests for blood analysis.
Nutritional products include a range of pediatric and adult nutritional products manufactured, marketed, and sold worldwide. These products are generally marketed and sold directly to customers and to institutions, wholesalers, retailers, healthcare facilities, government agencies, and third-party distributors from Abbott-owned distribution centers or third-party distributors. Its products include various forms of prepared infant formula and follow-on formula, including Similac, Similac Advance, Similac Advance with EarlyShield, Similac with Iron, Similac Sensitive, Similac Sensitive RS, Similac Go&Grow, Similac NeoSure, Similac Organic, Similac Special Care, Similac Total Comfort, Similac For Supplementation, Isomil Advance, Isomil, Alimentum, Gain, and Grow; adult and other pediatric nutritional products, including Ensure, Ensure Plus, Ensure Muscle Health, Ensure (with Nutrivigor), Glucerna, Glucerna Hunger Smart, ProSure, PediaSure, PediaSure Sidekicks, EleCare, Juven, Abound, and Pedialyte; nutritional products used in enteral feeding in healthcare institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego (Enteral Pump) and Freego sets, and Nepro, and Zone Perfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge. In addition, certain nutritional products sold as Gain, Grow, PediaSure, PediaSure Sidekicks, Pedialyte, Ensure, Zone Perfect, EAS/Myoplex, and Glucerna are also promoted directly to the public by consumer marketing in select markets.
Vascular products include a range of coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease manufactured, marketed and sold worldwide. In the United States, the segment's products are marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.
Vascular products segment’s products include Xience Xpedition, Xience Prime, Xience nano, Xience V, and Xience Pro, drug-eluting coronary stent systems developed on the Multi-Link Vision platform; Absorb, a drug-eluting coronary bioresorbable vascular scaffold, Multi-Link 8, Multi-Link Vision and Multi-Link Mini Vision, coronary metallic stents; TREK and Voyager, coronary balloon dilatation products; Hi-Torque Balance Middleweight Elite and ASAHI coronary guidewires (licensed from Asahi Intecc Co., Ltd.); MitraClip, a percutaneous mitral valve repair system; Supera Veritas, a stent system for the treatment of biliary strictures related to cancer in the United States and peripheral artery disease outside the United States; StarClose SE and Perclose vessel closure devices, and Acculink/Accunet and Xact/Emboshield NAV, carotid stent systems.
The principal products in Abbott's other businesses include blood glucose and continuous glucose monitoring systems, test strips, data management software and accessories for people with diabetes, including the FreeStyle product line, and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. These products are marketed worldwide and generally sold directly to wholesalers, government agencies, healthcare facilities, mail order pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Some of these products are marketed and distributed through distributors. Blood glucose monitoring systems, contact lens care products, and dry eye products are also marketed and sold over-the-counter to consumers.
C/O TAX DEPT D367 & AP6D
100 Abbott Park Road
ABBOTT PARK IL 60064-3500
Company Web Links
- Abbott to Present at J.P. Morgan Healthcare Conference
- Abbott Commences Tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022
- Abbott Announces Increase in Quarterly Dividend
- Abbott Completes Acquisition of Veropharm
- Health Care Equipment and Supplies Equities Scrutiny - Abbott Laboratories, Zimmer Holdings, Varian Medical Systems, Edwards Lifesciences, and Cerus